Company intelligence / Profile preview

Huiankai

Ownership: Private
Employees: ~350
Development stage: Commercial

Overview

HuiKang has developed original biological drugs such as a recombinant human lysozyme eye drop and class I new biological products. The company also commercializes medical devices like absorbable gene recombinant collagen hemostatic sponges and high-tech skincare products. No specific clinical trial data or regulatory approvals are detailed in public sources.

Therapeutic areas: OtherDermatologyOphthalmologyHematology
Modalities: Recombinant proteinPeptidesSmall molecule (in raw materials)Biologic
Industry: Biotech

Partnerships

Collaborations with oversea experts from Australia/South KoreaScientific research projects with seven domestic/international universities

Beyond the preview

Go deeper on Huiankai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huiankai.

Explore the full profile